Feedback PLC 12 month contract for Sussex CDC pilot extension (3346Y)
September 06 2022 - 2:00AM
UK Regulatory
TIDMFDBK
RNS Number : 3346Y
Feedback PLC
06 September 2022
Prior to publication, the information contained within this
announcement was deemed by the Company to constitute inside
information as stipulated under the Market Abuse Regulations (EU)
No. 596/2014 ("MAR"). With the publication of this announcement,
this information is now considered to be in the public domain.
Feedback plc
Feedback awarded twelve month contract for pilot extension in
Sussex Community Diagnostic Centre
-- GBP450,000 contract to cover a 12 month extension of initial
pilot phase of Sussex Health and Care Partnership Integrated Care
System ("Sussex ICS") development programme with Queen Victoria
Hospital ("QVH").
-- Follows on from the previously announced memorandum of
understanding ("MOU") to embark on a pilot scheme, providing
services with the exemplar Sussex ICS Community Diagnostic Centre
("CDC") site at QVH.
-- The contract enables extension of the current pilot programme
whilst QVH embarks on a formal procurement process for a solution
in the long term. This procurement is anticipated to be completed
in March 2023. The Company will submit a bid in this subsequent
procurement.
London, 6th September 2022 : Feedback plc (AIM: FDBK, "Feedback"
or the "Company"), the specialist clinical infrastructure company,
announces that it has been awarded a twelve-month contract to
provide its CDC solution in order to facilitate an extension of the
current CDC pilot in Sussex to further GP practices and to enable
the adoption of further clinical pathways. The discounted contract
is valued at GBP450,000 and covers the period from 31(st) March
2022 when the pilot MOU formally ended. The contract will run until
31(st) March 2023 by which point QVH expect to have concluded a
formal procurement for the next phase of the CDC programme rollout,
as is required by NHS procurement policies. Feedback intends to
submit a bid in this subsequent procurement phase.
The contract comes as the first live patients go through the CDC
pilot as a result of the MOU signed with the Sussex ICS in October
2021, which was to embark on a pilot scheme to establish
symptom-based pathway models for CDC services using Feedback's
digital infrastructure solutions Bleepa and CareLocker. QVH in
Sussex is one of the UK's exemplar CDC sites and the first to
deliver end-to-end symptom-based pathways through the CDC
programme. As previously announced, the deployment of Feedback's
product suite in the Sussex ICS is intended to be used as a
blueprint model for future CDC digital infrastructure models across
the UK.
Bleepa's patient-centric design enables clinicians to
collaborate on a patient-by-patient basis across geography, with
the clinical discussion forming an auditable record for the patient
episode that is subsequently shared with all stakeholders.
CareLocker's ability to integrate with multiple clinical systems
and centralise data around an individual patient means that all the
diagnostic results can be seen in one place across all provider
groups, ensuring that relevant data can be collected from multiple
clinical settings, travels with the patient and is always available
to clinicians.
Dr Tom Oakley, CEO of Feedback, said: "QVH and the broader
Sussex team have been great partners in delivering this end-to-end
clinical solution. This contract recognises the initial stage of
our work together and enables us to proceed to a more formal
working arrangement, pending a successful procurement exercise.
Together we have demonstrated that CDCs can be used to
successfully deliver cross-provider symptom-based diagnostic
pathways that transform the patient journey within the NHS and we
expect to be able to show a meaningful impact on patient waiting
lists as a result. ICSs need to adopt a symptom-based pathway
approach to CDCs if they are going to deliver the expected impact
on cancer and elective care waiting times. This pilot is the first
example in the country of how this can be delivered and our digital
infrastructure is an essential component of delivering it."
Further information on Feedback and its products can be found on
the Company's website:
https://fbkmed.com/feedback-plc/reports-and-presentations/
-Ends-
Enquiries:
Feedback plc +44 (0) 20 3997 7634
Tom Oakley, CEO IR@fbk.com
Anesh Patel, CFO
Panmure Gordon (UK) Limited
(NOMAD and Broker)
Emma Earl/Freddy Crossley (Corporate
Finance)
Rupert Dearden (Corporate Broking) +44 (0)20 7886 2500
Walbrook PR Ltd Tel: 020 7933 8780 or feedbackplc@walbrookpr.com
Paul McManus/Nick Rome/Joe Walker 07980 541 893 or 07748 325 236
or 07407 020 470
About Feedback
Feedback plc helps clinical teams to make better decisions
faster for patients. We design products that enhance clinician
access to patient data and to their colleagues. Our unique approach
centres around individual patient episodes, into which we pull
relevant clinical data from hospital systems and around which we
build remote clinical teams for collaboration. As a result, we
produce a digital infrastructure that makes patient data available
to clinicians in multiple settings, in a format that enables them
to meaningfully interact with it, providing flexibility to
clinicians and free movement of patients between provider settings
- clinicians can practice from anywhere and patients can attend any
care provider for investigation and treatment.
Our products Bleepa and CareLocker work together to deliver
unparalleled value to our customers. Bleepa is our application
layer and sits on top of CareLocker as our data layer. Bleepa is a
clinician facing platform that displays clinical results from a
patient's CareLocker at a certified and regulated quality, that is
suitable for clinical use and enables dialogue on a
patient-by-patient basis with colleagues through a secure,
auditable chat interface that links back to the patient medical
record. CareLocker provides an alternative to traditional
system/cloud storage and stores clinical data at an individual
patient level, wrapping relevant clinical data around the specific
patient, ensuring that data is always linked to the patient and is
available to them and any care setting that they attend - it is a
federated data architecture with the patient as the tenant.
The Company has a number of growth opportunities domestically
and internationally across a range of markets including the NHS,
the veterinary market and private healthcare providers and its
highly scalable Software as a Service ("SaaS")-based revenue model
is expected to provide increasing levels of visibility as the
Company grows its customer base.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
CNTLAMFTMTTMBLT
(END) Dow Jones Newswires
September 06, 2022 02:00 ET (06:00 GMT)
Feedback (LSE:FDBK)
Historical Stock Chart
From Jul 2024 to Jul 2024
Feedback (LSE:FDBK)
Historical Stock Chart
From Jul 2023 to Jul 2024